Amgen's biosimilar candidate to Stelara shows no clinically meaningful differences in study
Sundry Photography/iStock Editorial via Getty Images


Amgen (NASDAQ:AMGN) on Monday said its phase 3 study evaluating the efficacy and safety of its biosimilar candidate ABP 654 vs Johnson & Johnson's (JNJ) Stelara in adult patients with moderate to severe plaque psoriasis met its main goal.

"The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and Stelara," said Amgen in a statement.
A preliminary primary analysis of the study evaluated the percentage improvement over a period of time of the severity of the psoriasis area. The analysis showed a mean difference of percentage improvement between ABP 654 and Stelara of 0.14, which was within the prespecified margins.
ABP 654 - among a total of 11 biosimilars in Amgen's portfolio - is being developed as a biosimilar candidate to J&J's Stelara, which is an FDA-approved treatment for Crohn's disease, colitis, psoriasis and arthritis.
AMGN stock earlier closed -0.8% at $251.93.